We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-13.93%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$145M
AUM Growth
-$28.6M
Cap. Flow
-$1.67M
Cap. Flow %
-1.15%
Top 10 Hldgs %
75.3%
Holding
32
New
2
Increased
12
Reduced
8
Closed
7

Top Buys

1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.7M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$2.53M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$2.06M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$1.54M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.3M

Top Sells

1
EBS icon
Emergent Biosolutions
EBS
+$2.36M
2
CPIX icon
Cumberland Pharmaceuticals
CPIX
+$2M
3
CHMA
Chiasma, Inc. Common Stock
CHMA
+$1.56M
4
VSTM icon
Verastem
VSTM
+$1.48M
5
MTNB icon
Matinas BioPharma
MTNB
+$1.29M

Sector Composition

1 Healthcare 93.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$6.08B
$19.1M 13.16%
268,482
+28,032
+12% +$2.06M
VNDA icon
2
Vanda Pharmaceuticals
VNDA
$327M
$18.9M 13.02%
1,341,943
+81,655
+6% +$1.3M
AMRN
3
Amarin Corp
AMRN
$292M
$18M 12.42%
46,530
-789
-2% -$289K
BDSI
4
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$12.9M 8.85%
2,764,475
+1,225,038
+80% +$5.7M
ADMS
5
DELISTED
Adamas Pharmaceuticals
ADMS
$8.83M 6.08%
1,423,578
+439,249
+45% +$2.53M
APEN
6
DELISTED
Apollo Endosurgery, Inc.
APEN
$8.39M 5.77%
2,580,518
– –
NEOS
7
DELISTED
Neos Therapeutics, Inc
NEOS
$6.41M 4.42%
4,971,014
+459,510
+10% +$845K
ALIM
8
DELISTED
Alimera Sciences
ALIM
$5.73M 3.95%
429,300
-2,941
-0.7% -$41.4K
CPIX icon
9
Cumberland Pharmaceuticals
CPIX
$102M
$5.55M 3.82%
871,762
-330,213
-27% -$2M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$400M
$5.53M 3.8%
65,484
+4,644
+8% +$418K
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.35M 3.68%
4,113,522
+38,578
+0.9% +$52.9K
HTGM
12
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$4.62M 3.18%
15,475
-279
-2% -$116K
OPNT
13
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$4.18M 2.88%
315,468
+20,574
+7% +$249K
XOMA
14
DELISTED
Xoma
XOMA
$4.02M 2.77%
270,449
+43,019
+19% +$646K
APVO icon
15
Aptevo Therapeutics
APVO
$5.91M
– –
0
– –
CTIC
16
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.35M 2.31%
3,904,400
-95,600
-2% -$88.2K
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.14M 2.16%
227,900
+100,676
+79% +$1.54M
AFMD
18
DELISTED
Affimed
AFMD
$2.05M 1.41%
71,575
+21,001
+42% +$707K
FOMX
19
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.55M 1.07%
651,211
-78,793
-11% -$235K
VIVE
20
DELISTED
VIVEVE MED INC
VIVE
$1.29M 0.89%
3,403
– –
IDXG
21
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$1.27M 0.88%
175,318
+31,915
+22% +$234K
MTNB icon
22
Matinas BioPharma
MTNB
$2.2M
$573K 0.39%
13,372
-26,788
-67% -$1.29M
SBBP
23
DELISTED
Strongbridge Biopharma plc.
SBBP
$508K 0.35%
162,244
-24,830
-13% -$91.2K
NVLN
24
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$383K 0.26%
+491,096
New +$546K
MOTS
25
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$107K 0.07%
+117
New +$131K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Stonepine Capital Management held 32 positions worth $145M, down 16% from $174M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Stonepine Capital Management's Q2 2019 filing shows 2 new, 12 increased, 8 reduced and 7 closed positions. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K. The largest sale was Emergent Biosolutions, an estimated $2.36M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2019 buy was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K.
  • Stonepine Capital Management added most to BioDelivery Sciences International, Inc. in Q2 2019, an estimated $5.7M increase.
  • Stonepine Capital Management's biggest Q2 2019 reduction was Cumberland Pharmaceuticals, cutting an estimated $2M.
  • Stonepine Capital Management fully exited Emergent Biosolutions in Q2 2019, selling an estimated $2.36M.
  • Stonepine Capital Management's ten largest holdings make up 75% of its $145M portfolio in Q2 2019.
  • Stonepine Capital Management opened 2 new positions and closed 7 in Q2 2019.
  • Stonepine Capital Management's portfolio value fell 16% quarter-over-quarter to $145M.

Based on Stonepine Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.